Jardiance Alcohol Interaction Profile: What Patients and Clinicians Need to Know

How Empagliflozin Works and Why Alcohol Complicates It

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing roughly 60 to 90 g of glucose to be excreted in urine each day in adults with type 2 diabetes. [1] This glucosuria is accompanied by an osmotic diuresis: the FDA-approved prescribing information for Jardiance lists volume depletion as a recognized adverse effect and recommends assessing renal function and volume status before initiation. [2]

Alcohol adds its own diuretic load. Ethanol suppresses antidiuretic hormone (vasopressin) in a dose-dependent fashion, increasing urine output independent of fluid intake. [3] When both agents act simultaneously, the combined diuretic effect can produce clinically meaningful hypovolemia, especially in warm weather, during exercise, or in older adults with reduced thirst perception.

The Pharmacodynamic Overlap

The empagliflozin-alcohol interaction is primarily pharmacodynamic, not pharmacokinetic. Studies of SGLT2 inhibitor metabolism show that empagliflozin is glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, none of which are materially induced or inhibited by ethanol at typical drinking doses. [1] Plasma empagliflozin concentrations are therefore not substantially changed by alcohol. The danger lies in what both drugs do to the body simultaneously, not in altered drug levels.

Volume Status: The Shared Vulnerability

A 2015 EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg and 25 mg reduced the risk of cardiovascular death by 38% relative to placebo, partly through a proposed volume-offloading mechanism. [4] That same volume-offloading effect, however, means patients begin from a lower intravascular volume baseline before any alcohol is consumed. Even two standard drinks (28 g ethanol) can suppress vasopressin sufficiently to increase hourly urine output by 100 to 200 mL, according to data reviewed in a 2015 alcohol-pharmacology summary published via the National Institute on Alcohol Abuse and Alcoholism. [3]

Euglycemic Diabetic Ketoacidosis: The Most Serious Risk

Euglycemic DKA is a ketoacidotic state in which blood glucose may be below 250 mg/dL, making it easy to miss. The FDA issued a Drug Safety Communication in May 2015 warning that all approved SGLT2 inhibitors, including empagliflozin, had been associated with euglycemic DKA, and updated labeling accordingly. [5]

How Alcohol Raises DKA Risk on SGLT2 Inhibitors

Alcohol elevates ketone production through two mechanisms that overlap with SGLT2 inhibitor physiology:

1. Ethanol oxidation in the liver increases the NADH/NAD+ ratio, shifting metabolism toward ketogenesis and suppressing gluconeogenesis. [6]
2. SGLT2 inhibitors themselves raise circulating glucagon and lower insulin levels, which already push the liver toward fat oxidation and ketone production independent of diet. [7]

When these two ketogenic stimuli combine, particularly after a night of heavier drinking that also involves skipping a meal, the substrate for DKA is substantially greater than with either agent alone.

What the Case Reports Show

A 2016 case series published in Diabetes Care (Rawla et al. And multiple contemporaneous letters) documented euglycemic DKA in patients on SGLT2 inhibitors following events including prolonged fasting, very-low-carbohydrate diets, and significant alcohol intake. [8] The FDA MedWatch database had received more than 70 confirmed SGLT2-related DKA reports within the first year of the 2015 warning. [5] Clinicians reviewing those reports noted that many patients had blood glucose readings that would not trigger standard DKA suspicion, delaying diagnosis by hours to days.

Symptoms to Recognize

Euglycemic DKA may present with nausea, vomiting, abdominal pain, fatigue, and difficulty breathing despite a glucose reading that appears nearly normal. Patients who experience these symptoms after drinking while on Jardiance should seek emergency evaluation, not simply hydrate and wait.

Hypoglycemia Risk: When a Third Drug Enters the Picture

Empagliflozin alone carries a low intrinsic hypoglycemia risk because its action is glucose-dependent: SGLT2 excretion decreases as plasma glucose falls. [1] Alcohol alone, however, suppresses hepatic gluconeogenesis. A 2008 review in Diabetes Care by Richardson et al. Confirmed that moderate-to-heavy alcohol consumption blunts the counter-regulatory response to hypoglycemia and prolongs recovery time in people with diabetes. [9]

Combined Risk with Insulin or Sulfonylureas

When a patient takes empagliflozin alongside insulin or a sulfonylurea such as glipizide or glyburide, the hypoglycemia risk profile changes substantially. The ADA 2024 Standards of Medical Care in Diabetes states: "Alcohol can cause hypoglycemia (particularly in individuals who use insulin or insulin secretagogues) and should be consumed with food." [10] In this three-way combination (SGLT2 inhibitor plus secretagogue or insulin, plus alcohol), the counter-regulatory reserve is eroded from two directions at once.

Patients on these regimens who drink should monitor blood glucose more frequently, eat carbohydrates alongside any alcohol consumed, and carry fast-acting glucose tablets.

Blood Pressure and Orthostatic Hypotension

Empagliflozin produces a clinically meaningful blood-pressure reduction. In a pre-specified analysis of EMPA-REG OUTCOME, systolic blood pressure fell by 3 to 4 mmHg and diastolic by 1 to 2 mmHg compared with placebo, without compensatory heart-rate increase. [4] That modest but real antihypertensive effect is part of why the drug is useful in heart failure and chronic kidney disease, but it also lowers the threshold for symptomatic orthostatic hypotension.

Alcohol's Independent Blood-Pressure Effects

Acute alcohol ingestion causes peripheral vasodilation. A meta-analysis of 32 randomized trials published in the Cochrane Database of Systematic Reviews in 2019 (Roerecke et al., N=767 participants) found that medium-to-high doses of alcohol (greater than 25 g, or roughly two standard drinks) produced a mean systolic blood-pressure decrease of 3.49 mmHg in the first six hours. [11]

Adding a 3 to 4 mmHg systolic reduction from empagliflozin to a 3.49 mmHg acute reduction from two drinks places some patients in territory where standing quickly may trigger dizziness or falls. Older adults, patients already on antihypertensive therapy, and those with autonomic neuropathy face the greatest risk.

Practical Guidance on Posture and Hydration

Patients who choose to drink should rise slowly from sitting or lying positions, drink one glass of water per alcoholic drink, and avoid hot tubs or saunas on the same evening. These measures do not eliminate risk but they reduce the amplitude of the orthostatic drop.

Kidney Function: An Underappreciated Variable

Empagliflozin's renoprotective effects are now well-established. The EMPA-KIDNEY trial (N=6,609) published in the New England Journal of Medicine in 2023 showed that empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% relative to placebo (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001). [12]

Chronic or heavy alcohol use independently damages renal tubular function and raises the risk of acute kidney injury (AKI), particularly in states of volume depletion. Because empagliflozin's glucose-lowering effect depends on adequate glomerular filtration rate (eGFR >30 mL/min/1.73 m² for its glucose-lowering indication), volume-depleted states that transiently lower eGFR can blunt the drug's effectiveness while simultaneously increasing the risk of AKI. [2]

Who Faces the Highest Renal Risk

Patients with baseline CKD stages 3 to 4 who are prescribed empagliflozin for its cardiorenal benefits (where it is approved down to eGFR >20 for heart failure or CKD indications) face a narrower safety margin with alcohol. A single episode of significant dehydration from an evening of drinking may push eGFR below the threshold for safe dosing.

Liver Considerations: Alcoholic Liver Disease and SGLT2 Inhibitors

Empagliflozin is metabolized primarily by hepatic and intestinal glucuronidation. Mild-to-moderate hepatic impairment (Child-Pugh A or B) does not substantially alter empagliflozin exposure, according to the prescribing information. [2] Severe hepatic impairment (Child-Pugh C) has not been studied, and the label recommends caution.

Patients with alcoholic liver disease who progress to cirrhosis may have unpredictable empagliflozin pharmacokinetics, altered gluconeogenesis capacity, and thrombocytopenia that complicates the clinical picture. For these patients, the alcohol-empagliflozin combination should be reviewed with a hepatologist.

Non-Alcoholic Fatty Liver Disease and Emerging Data

A separate consideration: SGLT2 inhibitors show early promise in non-alcoholic fatty liver disease (NAFLD), with a 2021 meta-analysis in Diabetes, Obesity and Metabolism (Raj et al.) showing meaningful reductions in liver fat fraction with SGLT2 inhibitor use. [13] Concurrent alcohol use could undermine any hepatic benefit by re-introducing the primary driver of hepatic steatosis the drug is trying to address.

What ADA, FDA, and Prescribing Label Say

The convergence of three authoritative sources defines the practical guidance framework for this interaction:

FDA Jardiance Label (2023 revision): The label lists volume depletion under warnings and precautions, identifies DKA as a serious risk requiring prompt evaluation, and flags that patients should be counseled about signs of DKA, including during periods of restricted food or fluid intake. [2]

ADA 2024 Standards of Medical Care: Section 5 on Facilitating Behavior Change and Well-being states that patients with diabetes should limit alcohol to a maximum of one drink per day for women and two drinks per day for men, that alcohol should always be consumed with food, and that patients on insulin or secretagogues need to take specific precautions for hypoglycemia. [10]

EMPA-REG OUTCOME Investigator Guidance: The trial's baseline restriction excluded patients with active alcohol use disorder, meaning that the cardiovascular and renal benefits established in EMPA-KIDNEY and EMPA-REG OUTCOME were documented in populations who were largely light-to-moderate drinkers at most. Extrapolating those benefits to heavy drinkers is not supported by trial data.

The ADA guideline document states directly: "Alcohol consumption may increase the risk of hypoglycemia for those individuals taking insulin or insulin secretagogues." [10] That statement, combined with the FDA's DKA and volume-depletion warnings, forms the clinical basis for recommending that patients on Jardiance minimize or avoid alcohol, particularly binge drinking.

Practical Rules for Patients Who Choose to Drink

The following guidance applies to adults without active alcohol use disorder, without history of SGLT2-related DKA, without CKD stage 4 or worse, and who have discussed this with their prescriber:

The One-Drink Rule and Food Pairing

No more than one standard drink for women or two for men per occasion, consumed with a carbohydrate-containing meal. A standard drink in the United States is 14 g of ethanol: one 12 oz beer at 5%, one 5 oz glass of wine at 12%, or 1.5 oz of 80-proof spirits. [3] Drinking on an empty stomach sharply raises the risk of both hypoglycemia (via suppressed gluconeogenesis) and ketogenesis.

Hydration Protocol

One 8 oz glass of water before drinking, and one additional glass of water per alcoholic drink consumed. This does not fully compensate for the combined diuretic effect of empagliflozin plus ethanol, but it reduces the magnitude of volume depletion. Patients should weigh themselves the morning after any drinking occasion: a loss of more than 2 lb (approximately 1 kg) overnight suggests significant dehydration and warrants extra oral rehydration before the next empagliflozin dose.

Blood Glucose Monitoring

Patients on insulin or sulfonylureas should check glucose before drinking, two hours after the first drink, and before bed. The goal is to identify any downward trend early, when it can be corrected with carbohydrates rather than emergency treatment.

When to Hold the Dose

Patients who experience vomiting or are unable to eat after drinking should hold their empagliflozin dose that morning and contact their prescriber. Taking empagliflozin while volume-depleted, ketone-primed from a night of drinking, and unable to eat substantially raises DKA risk. The prescribing information supports temporary dose interruption in the setting of acute illness or restricted intake. [2]

Absolute Avoidance Situations

Alcohol should be avoided entirely on empagliflozin in these situations: history of any prior DKA episode, eGFR persistently below 30 mL/min/1.73 m², active or recovering alcoholic liver disease (Child-Pugh B or C), concurrent very-low-carbohydrate or ketogenic diet, planned surgical procedure within 48 hours (when empagliflozin is already being held), and pregnancy.

Monitoring Parameters Clinicians Should Review

Before any patient on empagliflozin discloses regular alcohol use, the clinician visit should address the following:

• Baseline eGFR and trend over the past 6 to 12 months
• Concurrent medications that lower blood pressure or glucose
• History of prior DKA or ketosis-prone diabetes phenotype
• Liver function tests if alcohol use exceeds 7 drinks per week for women or 14 for men
• Orthostatic blood pressure measurement if symptomatic dizziness has been reported
• Urine ketone baseline if the patient follows a low-carbohydrate diet

A serum beta-hydroxybutyrate level above 1.0 mmol/L in an outpatient setting warrants clinical concern and should prompt evaluation for euglycemic DKA before alcohol counseling alone is offered as reassurance.